am-555s has been researched along with Carcinoma--Lewis-Lung* in 1 studies
1 other study(ies) available for am-555s and Carcinoma--Lewis-Lung
Article | Year |
---|---|
TAC-101 (4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid) inhibits spontaneous mediastinal lymph node metastasis produced by orthotopic implantation of Lewis lung carcinoma.
The anti-tumor and anti-metastatic effects of 4-[3,5-bis(trimethylsilyl)benzamido]benzoic acid (TAC-101) were investigated using our established lung cancer model. Orthotopic implantation of Lewis lung carcinoma (LLC) cells into the lung parenchyma produced a solitary tumor nodule in the lung followed by mediastinal lymph node metastasis. Daily oral administration of TAC-101 at doses ranging from 4 to 16 mg/kg resulted in a significant inhibition of lymphatic metastasis (inhibition rate=57 to 76%), while only the dose of 16 mg/kg significantly inhibited tumor growth at the implanted sites (inhibition rate=46%). Combined treatment with cis-diamminedichloroplatinum (CDDP) and TAC-101 (8 mg/kg, p.o., daily) enhanced the anti-tumor effect of CDDP (7 mg/kg, i.v., bolus) against both the growth of implanted tumor and lymphatic metastasis. In addition, this combined treatment significantly prolonged the survival time of LLC tumor-bearing mice as compared to treatment with each agent alone. The anti-activating protein-1 (AP-1) activity of TAC-101 caused inhibition of LLC cell invasion through the repression of expression of urokinase-type plasminogen activator and its receptor. The anti-invasive activity of TAC-101 may be involved in its in vivo anti-metastatic activity. These findings suggest that TAC-101 is a novel anti-cancer agent that may improve the therapeutic modalities for lung cancer patients with metastatic disease. Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Lewis Lung; Cisplatin; Drug Screening Assays, Antitumor; Female; Lung Neoplasms; Lymphatic Metastasis; Mediastinum; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Neoplasm Transplantation; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factor AP-1; Trimethylsilyl Compounds; Urokinase-Type Plasminogen Activator | 1999 |